Piper Sandler raised the firm’s price target on Health Catalyst to $12 from $11 and keeps an Overweight rating on the shares. The analyst believes that “improving end market and transformational commercial strategy” will lead to “10% adjusted EBITDA margins and double-digit revenue growth in 2025,” and the firm is a buy of Health Catalyst into the new year.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HCAT: